

## **EXECUTIVE MANAGEMENT CHANGES**

### **HIGHLIGHTS**

- **Dr Jurgen Lindner joins NSB as an expert consultant in manufacturing, drug development and regulatory affairs**
- **Dr Anton Uvarov transitions to Non-executive Director after serving as Executive Director since the Company's listing**

NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) ("**NeuroScientific**" or "**the company**") is pleased to announce the appointment of Dr Jurgen Lindner as a consultant. Dr Lindner has a PhD in neurosciences, and is a pharmaceutical professional with extensive experience in drug development and the manufacture of therapeutic products. He also has a strong track record of managing quality, compliance and regulatory affairs, and developing commercially viable solutions in a highly regulated environment. Dr Lindner's expertise will be instrumental as the Company prepares a new submission for ethics approval for EmtinB™ in the coming months.

Additionally, after working as an Executive Director for NSB since the Company listed in 2018, Dr Anton Uvarov is transitioning to a Non-executive Director in order to continue to support the Company and provide expert knowledge in his field. Dr Uvarov's resignation from his Executive position is effective today, and for his services as a Non-executive Director, he will be paid a fee of \$55,000 per annum. The Company would like to thank Dr Uvarov for his commitment and service to the company as an executive for the last 4 years and his continued commitment to NSB.

**Paul Rennie commented:** "I am very excited for Dr Lindner's addition to the NSB team, and his knowledge and expertise will be vital for the Company's strategy. I would like to thank Dr Uvarov for his commitment and service to the company as an executive for the last 4 years and his continued commitment to NSB."

This announcement is authorised by the board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS-

For more information please contact:

Paul Rennie  
Non-executive Chairman  
pr@neuroscientific.com  
+ 61 9 6382 1805

Abby Macnish-Niven  
CFO and Company Secretary  
ir@neuroscientific.com  
+ 61 9 6382 1805

**About NeuroScientific Biopharmaceuticals Ltd**

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB™, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit [www.neuroscientific.com](http://www.neuroscientific.com)

**About EmtinB™**

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinB™ in humans.